| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HCII |
| Uniprot No | P05546 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-499aa |
| 氨基酸序列 | GSKGPLDQLEKGGETAQSADPQWEQLNNKNLSMPLLPADFHKENTVTNDW IPEGEEDDDYLDLEKIFSEDDDYIDIVDSLSVSPTDSDVSAGNILQLFHG KSRIQRLNILNAKFAFNLYRVLKDQVNTFDNIFIAPVGISTAMGMISLGL KGETHEQVHSILHFKDFVNASSKYEITTIHNLFRKLTHRLFRRNFGYTLR SVNDLYIQKQFPILLDFKTKVREYYFAEAQIADFSDPAFISKTNNHIMKL TKGLIKDALENIDPATQMMILNCIYFKGSWVNKFPVEMTHNHNFRLNERE VVKVSMMQTKGNFLAANDQELDCDILQLEYVGGISMLIVVPHKMSGMKTL EAQLTPRVVERWQKSMTNRTREVLLPKFKLEKNYNLVESLKLMGIRMLFD KNGNMAGISDQRIAIDLFKHQGTITVNEEGTQATTVTTVGFMPLSTQVRF TVDRPFLFLIYEHRTSCLLFMGRVANPSRS |
| 预测分子量 | 56 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与HCII(肝素辅因子II)重组蛋白相关的代表性文献摘要(基于公开研究整理，非真实文献引用)：
---
1. **标题**: *"Expression and Functional Characterization of Recombinant Human Heparin Cofactor II"*
**作者**: Tollefsen DM, et al.
**摘要**: 研究利用哺乳动物细胞表达系统成功制备重组HCII蛋白，证实其与肝素结合后抑制凝血酶的活性，并分析其糖基化修饰对功能的影响，为抗凝血机制研究提供基础。
2. **标题**: *"Recombinant HCII Inhibits Arterial Thrombosis in a Rabbit Model"*
**作者**: Church FC, et al.
**摘要**: 通过动物实验证明，外源性重组HCII可通过增强肝素介导的凝血酶抑制，显著减少动脉损伤模型中的血栓形成，提示其在抗血栓治疗中的潜在应用价值。
3. **标题**: *"High-Yield Production of Recombinant HCII Using Baculovirus-Insect Cell System"*
**作者**: He L, et al.
**摘要**: 开发基于杆状病毒-昆虫细胞的重组HCII高效表达体系，优化纯化工艺后获得高纯度蛋白，活性与天然HCII相当，为大规模制备提供技术方案。
---
(注：以上为模拟文献摘要，实际文献需通过PubMed/Google Scholar等平台检索关键词如“recombinant heparin cofactor II”获取。)
**Background of HCII Recombinant Protein**
Heparin Cofactor II (HCII), a serine protease inhibitor (serpin), plays a critical role in regulating blood coagulation by inhibiting thrombin, a key enzyme in the clotting cascade. Unlike its counterpart antithrombin III, HCII specifically targets thrombin in a glycosaminoglycan-dependent manner, showing high affinity for heparin and dermatan sulfate. This unique mechanism allows HCII to modulate thrombin activity in both intravascular and extravascular environments, contributing to hemostatic balance and tissue protection.
HCII recombinant protein is engineered using biotechnological approaches, typically expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications. Recombinant HCII retains the functional domains of the native protein, including the thrombin-binding site and glycosaminoglycan-binding regions, enabling its use in research and therapeutic contexts. Its production addresses limitations of plasma-derived HCII, such as scarcity and contamination risks, while offering scalable and consistent yields.
Studies highlight HCII’s dual role: beyond anticoagulation, it exhibits anti-inflammatory and cytoprotective properties, potentially aiding in conditions like atherosclerosis or ischemia-reperfusion injury. Recombinant HCII is also a valuable tool for dissecting thrombin regulation mechanisms and screening modulators of hemostasis.
Ongoing research explores its therapeutic potential, particularly in thrombotic disorders resistant to conventional anticoagulants. By leveraging recombinant DNA technology, HCII’s applications extend from basic science to drug development, underscoring its significance in understanding and managing coagulation-related pathologies.
×
